Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher B Granger

Showing results (431-440 of 910) with videos related to

Pageof 91
Sort By:
American Heart Journal|December 15, 2010
Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinuxPhilippe Gabriel Steg, Shamir Mehta, Sanjit Jolly, et al.
Critical Care Medicine|December 24, 2009
Evolution of the coronary care unit: clinical characteristics and temporal trends in healthcare delivery and outcomesJason N Katz, Bimal R Shah, Elizabeth M Volz, et al.
Heart (British Cardiac Society)|November 1, 2016
Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillationM Cecilia Bahit, Renato D Lopes, Daniel M Wojdyla, et al.
JAMA Cardiology|July 21, 2016
Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical TrialZiad Hijazi, Stefan H Hohnloser, Ulrika Andersson, et al.
Circulation. Cardiovascular Quality and Outcomes|September 3, 2010
Impact of a statewide ST-segment-elevation myocardial infarction regionalization program on treatment times for women, minorities, and the elderlySeth W Glickman, Christopher B Granger, Fang-Shu Ou, et al.
American Heart Journal|July 12, 2011
Cardiogenic shock and heart failure post-percutaneous coronary intervention in ST-elevation myocardial infarction: observations from "Assessment of Pexelizumab in Acute Myocardial Infarction"John K French, Paul W Armstrong, Eric Cohen, et al.
American Heart Journal|December 16, 2014
Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trialChristopher B Granger, Renato D Lopes, Michael Hanna, et al.
Journal of Cardiovascular Translational Research|August 15, 2015
A Guide for a Cardiovascular Genomics Biorepository: the CATHGEN ExperienceWilliam E Kraus, Christopher B Granger, Michael H Sketch, et al.
European Heart Journal|January 18, 2006
Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomesAndrés Orlandini, Rafael Díaz, Daniel Wojdyla, et al.
Circulation|August 20, 2003
Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trialKenneth W Mahaffey, Christopher B Granger, Jose C Nicolau, et al.
Pageof 91

Showing results (431-440 of 910) with videos related to

Sort By:
Pageof 91
American Heart Journal|December 15, 2010
Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinuxPhilippe Gabriel Steg, Shamir Mehta, Sanjit Jolly, et al.
Critical Care Medicine|December 24, 2009
Evolution of the coronary care unit: clinical characteristics and temporal trends in healthcare delivery and outcomesJason N Katz, Bimal R Shah, Elizabeth M Volz, et al.
Heart (British Cardiac Society)|November 1, 2016
Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillationM Cecilia Bahit, Renato D Lopes, Daniel M Wojdyla, et al.
JAMA Cardiology|July 21, 2016
Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical TrialZiad Hijazi, Stefan H Hohnloser, Ulrika Andersson, et al.
Circulation. Cardiovascular Quality and Outcomes|September 3, 2010
Impact of a statewide ST-segment-elevation myocardial infarction regionalization program on treatment times for women, minorities, and the elderlySeth W Glickman, Christopher B Granger, Fang-Shu Ou, et al.
American Heart Journal|July 12, 2011
Cardiogenic shock and heart failure post-percutaneous coronary intervention in ST-elevation myocardial infarction: observations from "Assessment of Pexelizumab in Acute Myocardial Infarction"John K French, Paul W Armstrong, Eric Cohen, et al.
American Heart Journal|December 16, 2014
Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trialChristopher B Granger, Renato D Lopes, Michael Hanna, et al.
Journal of Cardiovascular Translational Research|August 15, 2015
A Guide for a Cardiovascular Genomics Biorepository: the CATHGEN ExperienceWilliam E Kraus, Christopher B Granger, Michael H Sketch, et al.
European Heart Journal|January 18, 2006
Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomesAndrés Orlandini, Rafael Díaz, Daniel Wojdyla, et al.
Circulation|August 20, 2003
Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trialKenneth W Mahaffey, Christopher B Granger, Jose C Nicolau, et al.
Pageof 91